Page 1 of 1

This was a great press release, here's why

Posted: Thu Dec 10, 2020 5:53 pm
by biopearl123
While seemingly boiler plate the PR reminds of two things: 1. " Currently, no drug therapy has been shown prospectively to alter or delay disease progression. " Geron will likely be the first. 2. The MOA is directed at the malignant progenitor cell. This is unique and strikes at the root of the disease. Alteration of progression to higher risk and possibly AML may be shown. This will be big. Now buckle you seat belts, sit back relax and wait two years. I don't doubt that agents like Constellation's will be tested also in MDS but the mechanism of action may be alteration of maturation (like Lus) rather than a direct effect on the LCS and progenitors. I hope Dr. S and Co will elucidate this for us. There is reason to hope for the paradigm shift that was promised. bp